Higher serum and CSF GFAP levels were found to prognosticate worse outcomes of progression as well as brain atrophy, especially in the gray matter and independent of serum NfL, making it an important biomarker particularly because it is less associated with the acute clinical phase of the disease. This evidence concerns the gene NEFL and Brain atrophy.